Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating)’s stock price rose 1.2% during trading on Friday . The stock traded as high as $1.77 and last traded at $1.70. Approximately 1,603,696 shares changed hands during trading, a decline of 39% from the average daily volume of 2,613,958 shares. The stock had previously closed at $1.68.
Analysts Set New Price Targets
TCRT has been the topic of several research reports. Wells Fargo & Company raised shares of Alaunos Therapeutics from an “equal weight” rating to an “overweight” rating and set a $3.00 price objective on the stock in a research note on Wednesday, May 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alaunos Therapeutics in a research note on Monday, May 9th.
Alaunos Therapeutics Price Performance
The company has a 50 day moving average of $1.08. The stock has a market cap of $367.12 million, a PE ratio of -5.31 and a beta of 0.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.29 and a current ratio of 3.29.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $101,000. Steward Partners Investment Advisory LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $45,000. Gamble Jones Investment Counsel bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $76,000. Stephens Inc. AR bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $31,000. Finally, CIBC Private Wealth Group LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $51,000. Institutional investors own 52.16% of the company’s stock.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.